Transcranial Magnetic Stimulation in Children With Attention Deficit Hyperactivity Disorder (ADHD). A Safety Study
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Device: Transcranial Magnetic Stimulation
- Registration Number
- NCT01052064
- Lead Sponsor
- International Center for Neurological Restoration, Cuba
- Brief Summary
Low frequency repetitive Transcranial Magnetic Stimulation(rTMS) is a safe and tolerable procedure in children with Attention Deficit Hyperactivity Disorder(ADHD); it also could be a complement to the treatment of patients with poor symptomatic control to conventional treatment.
- Detailed Description
Attention Deficit Hyperactivity Disorder is a common disorder in the infancy; the majority of ADHD have good clinical response to amphetamines alone or in association with antiepileptic drugs. It is described that some patients(10-30%) with ADHD do not respond to conventional pharmacological and psycho- pedagogical treatment; in those patients non invasive brain stimulation methods could be a supplementary option for symptomatic control. There are not many published papers describing the effects of rTMS in persons younger than 18 years; so the first step to extent its use in pediatric population should be to obtain evidences about its tolerance and safety.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
- Ages eligible for Study: 7years to 12 years
- Genders Eligible for Study: Both
- History of convulsions
- Co-morbidity with other psychiatric or neurologic disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Transcranial magnetic stimulation Transcranial Magnetic Stimulation There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
- Primary Outcome Measures
Name Time Method Incidence of adverse events week 1,during treatment
- Secondary Outcome Measures
Name Time Method EEG changes in epileptiform or basal activity after treatment compared with the baseline last day of treatment
Trial Locations
- Locations (1)
International Center for Neurological Restoration
🇨🇺Havana, Cuba